CLINICAL EFFICACY OF SECUKINUMAB TREATMENT AFTER 12 WEEKS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Abstract
According to the obtained results, notable differences were observed between the two groups during treatment.
References
1. Baraliakos, X., Braun, J., Deodhar, A., Poddubnyy, D., Kivitz, A., Tahir, H., van den Bosch, F., Delicha, E. M., Talloczy, Z., & Fierlinger, A. (2019). Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open, 5(2). https://doi.org/10.1136/rmdopen-2019-001005
2. Halliday, A., Hacking, V., Jugl, S., Gunda, P., Nikoglou, E., Miles, L., & Graham, C. (2016). Budget Impact of Secukinumab For Ankylosing Spondylitis In The UK. Value in Health, 19(7). https://doi.org/10.1016/j.jval.2016.09.1095
3. Loricera, J., Galíndez-Aguirregoikoa, E., & Blanco, R. (2021). Safety of secukinumab for the treatment of active ankylosing spondylitis. Expert Opinion on Drug Safety, 20(6). https://doi.org/10.1080/14740338.2021.1851363
4. Lubrano, E., & Perrotta, F. M. (2016). Secukinumab for ankylosing spondylitis and psoriatic arthritis. In Therapeutics and Clinical Risk Management (Vol. 12). https://doi.org/10.2147/TCRM.S100091
5. Molica Colella, F., Zizzo, G., Parrino, V., Filosa, M. T., Cavaliere, R., Fazio, F., Molica Colella, A. B., & Mazzone, A. (2023). Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Advances in Rheumatology, 63(1). https://doi.org/10.1186/s42358-023-00295-2
6. Pehlivan, S. (2023). Ankylosing spondylitis. In Medical Nursing. https://doi.org/10.1111/j.1365-2044.1984.tb09445.x
7. Pavelka, K., Kivitz, A., Dokoupilova, E., Blanco, R., Maradiaga, M., Tahir, H., Pricop, L., Andersson, M., Readie, A., & Porter, B. (2017). Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3. Arthritis Research and Therapy, 19(1). https://doi.org/10.1186/s13075-017-1490-y
8. Purmonen, T., Puolakka, K., Mishra, D., Gunda, P., & Martikainen, J. (2019). Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. ClinicoEconomics and Outcomes Research, https://doi.org/10.2147/CEOR.S192235
9. Williams, T., Wadeley, A., Bond, D., Cavill, C., Freeth, M., & Sengupta, R. (2020). Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath. Clinical Rheumatology, 39(5). https://doi.org/10.1007/s10067-020-04944-5
10. Walsh, J. A., & Magrey, M. (2021). Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. In Journal of Clinical Rheumatology (Vol. 27, Issue 8). https://doi.org/10.1097/RHU.0000000000001575
11. Hwang, M. C., Ridley, L., & Reveille, J. D. (2021). Ankylosing spondylitis risk factors: a systematic literature review. In Clinical Rheumatology (Vol. 40, Issue 8). https://doi.org/10.1007/s10067-021-05679-7
12. Kameda, H., Kobayashi, S., Tamura, N., Kadono, Y., Tada, K., Yamamura, M., & Tomita, T. (2021). Non-radiographic axial spondyloarthritis. Modern Rheumatology, 31(2). https://doi.org/10.1080/14397595.2020.1830512
13. 19.Poddubnyy, D., & Sieper, J. (2020). Treatment of Axial Spondyloarthritis: What Does the Future Hold? In Current Rheumatology Reports (Vol. 22, Issue 9). https://doi.org/10.1007/s11926-020-00912-5
14. Baraliakos, X., Kivitz, A. J., Deodhar, A. A., Braun, J., Wei, J. C., Delicha, E. M., Talloczy, Z., & Porter, B. (2018). Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clinical and Experimental Rheumatology, 36(1)
15. Kocyigit, B. F., Sagtaganov, Z., Yessirkepov, M., & Akyol, A. (2023). Assessment of complementary and alternative medicine methods in the management of ankylosing spondylitis, rheumatoid arthritis, and fibromyalgia syndrome. In Rheumatology International (Vol. 43, Issue 4). https://doi.org/10.1007/s00296-022-05267-1
16. Dougados, M. (2020). Treat to target in axial spondyloarthritis: From its concept to its implementation. In Journal of Autoimmunity (Vol. 110). https://doi.org/10.1016/j.jaut.2019.102398
17. Sepriano, A. R., Rubio, R., Ramiro, S., Landewé, R., & van der Heijde, D. (2017). Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: A systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 76(5). https://doi.org/10.1136/annrheumdis-2016-210747
18. Abdurakhmanova, N., Akhmedov, K., Jabbarov, O., Rakhimova, M., Tagaeva, M., Khalmetova, F., & Tursunova, L. (2022). Clinical And Diagnostic Significance Of Anti-Cd74 In Patients With Ankylosing Spondylitis Of Uzbek Population.
19. Buranova S.N. Method of treatment aimed at the dynamics of cartilage oligomer matrix protein (COMP) in patients with osteoarthritis. // Turkish Journal of Physiotherapy and Rehabilitation; №32 (2) -P.4039-4041.
20. Xalmetova, F. I., X. S. Akhmedov, and S. N. Buranova. "The Role of Imaging Techniques in the Assessment of Structural Changes in the Joint in Reactive Arthritis." Academicia Globe: Inderscience Research 3.03 (2022): 186-189.
21. Blair, H. A. (2019). Secukinumab: A Review in Ankylosing Spondylitis. In Drugs (Vol. 79, Issue 4). https://doi.org/10.1007/s40265-019-01075-3
22. Braun, J., Baraliakos, X., Deodhar, A., Poddubnyy, D., Emery, P., Delicha, E. M., Talloczy, Z., & Porter, B. (2019). Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (United Kingdom), 58(5). https://doi.org/10.1093/rheumatology/key375
23. Dubash, S., Bridgewood, C., McGonagle, D., & Marzo-Ortega, H. (2019). The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. In Expert Review of Clinical Immunology (Vol. 15, Issue 2). https://doi.org/10.1080/1744666X.2019.1561281
24. Ebrahimiadib, N., Berijani, S., Ghahari, M., & Pahlaviani, F. G. (2021). Ankylosing spondylitis. In Journal of Ophthalmic and Vision Research (Vol. 16, Issue 3). https://doi.org/10.18502/jovr.v16i3.9440
25. Emery, P., van Keep, M., Beard, S., Graham, C., Miles, L. S., Jugl, S. M., Gunda, P., Halliday, A., & Marzo-Ortega, H. (2018). Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. PharmacoEconomics, 36(8). https://doi.org/10.1007/s40273-018-0675-9
26. Garcia-Montoya, L., Gul, H., & Emery, P. (2018). Recent advances in ankylosing spondylitis: Understanding the disease and management. In F1000Research (Vol. 7). https://doi.org/10.12688/F1000RESEARCH.14956.1
27. Garcia-Montoya, L., & Marzo-Ortega, H. (2018). The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. In Therapeutic Advances in Musculoskeletal Disease (Vol. 10, Issue 9). https://doi.org/10.1177/1759720X18787766
